ABVC BioPharma, Inc.
ABVC
$0.742
-$0.1725-18.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 380.00K | 117.10K | 1.20K | 2.20K | 15.90K |
| Total Other Revenue | 9.30K | -- | -- | -- | 15.90K |
| Total Revenue | 389.30K | 117.10K | 1.20K | 2.20K | 15.90K |
| Cost of Revenue | 300.00 | 200.00 | 300.00 | 139.20K | 29.60K |
| Gross Profit | 389.00K | 117.00K | 900.00 | -137.00K | -13.70K |
| SG&A Expenses | 301.20K | 1.05M | 3.38M | 1.75M | 2.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -16.90K | -- | -- | -- | 10.80K |
| Total Operating Expenses | 322.50K | 1.09M | 3.45M | 1.96M | 2.18M |
| Operating Income | 66.80K | -976.60K | -3.44M | -1.96M | -2.17M |
| Income Before Tax | -133.90K | -1.38M | -3.98M | -3.15M | -3.37M |
| Income Tax Expenses | 400.00 | -110.90K | -- | 175.30K | -1.00K |
| Earnings from Continuing Operations | -134.30K | -1.27M | -3.98M | -3.33M | -3.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -52.30K | 260.00K | 48.00K | 218.80K | 50.60K |
| Net Income | -186.60K | -1.01M | -3.93M | -3.11M | -3.32M |
| EBIT | 66.80K | -976.60K | -3.44M | -1.96M | -2.17M |
| EBITDA | 73.80K | -963.30K | -3.44M | -1.95M | -2.16M |
| EPS Basic | -0.02 | -0.09 | -0.40 | -0.47 | -0.82 |
| Normalized Basic EPS | -0.01 | -0.05 | -0.25 | -0.24 | -0.51 |
| EPS Diluted | -0.02 | -0.09 | -0.40 | -0.47 | -0.82 |
| Normalized Diluted EPS | -0.01 | -0.05 | -0.25 | -0.24 | -0.51 |
| Average Basic Shares Outstanding | 12.41M | 11.32M | 9.74M | 6.68M | 4.06M |
| Average Diluted Shares Outstanding | 12.41M | 11.32M | 9.74M | 6.68M | 4.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
